Test Catalog

Test Id : CSMOF

Order This Test

Controlled Substance Monitoring Panel, 11 Drug Classes, Screen Only, Immunoassay, Oral Fluid

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Monitoring acute (ie, short-term) drug use in addiction treatment or pain management settings as part of a rotational drug testing strategy

 

Presumptive screening for amphetamine, methamphetamine, opioids/opiates (targeting morphine, oxymorphone, oxycodone, hydrocodone, 6-monoacetylmorphine, tramadol, buprenorphine, fentanyl, and methadone), PCP (phencyclidine), cocaine metabolite (targeting benzoylecgonine), benzodiazepines (targeting oxazepam, lorazepam, and clonazepam), zolpidem, barbiturates (targeting phenobarbital), methylphenidate, and THC-COOH (marijuana metabolite) in oral fluid specimens

 

This test is not intended for forensic or medico-legal purposes (ie, employee drug testing or settings where chain-of-custody is required).

Highlights

The oral fluid sample, collected with the Quantisal device, is screened using a competitive immunoassay.

Method Name
A short description of the method used to perform the test

Competitive Chemiluminescent Immunoassay

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Controlled Substance Panel, OF

Aliases
Lists additional common names for a test, as an aid in searching

2-Ethylidene-1,5-Dimethyl-3,3-Dephenylpyrrolidine

Amobarbital (Amytal)

Amphetamines

Amytal (Amobarbital)

Angel Dust (Phencyclidine)

Barbita (Phenobarbital)

Barbiturates

Barbs

Butalbital (Fiorinal)

Benzoylecgonine (Cocaine Metabolite)

Buprenex

Suboxone

Subutex

Cannabinoids (Tetrahydrocannabinol)

Cocaine

Coke (Cocaine)

Codeine (Tylenol 3)

Crack (Cocaine)

Desoxyn (Methamphetamines)

Dilaudid (Hydromorphone)

Dolophine (Methadone)

Drocode (Dihydrocodone)

Drugs of Abuse

EDDP

Fentanyl (Sublimaze)

Heroin (as Morphine)

Hycodan (Hydrocodone)

Hydrocodone (Hycodan, Vicodin)

Hydrocodone (Norco)

Hydrmorphone (Dilaudid, Vicodin)

Innovar

"J" (Jane) (Tetrahydrocannabinol)

Jane (Tetrahydrocannabinol)

Killer Weed (Phencyclidine)

Lortab (Hydromorphone)

Luminal (Phenobarbital)

Marijuana (Tetrahydrocannabinol)

Mary Jane (Tetrahydrocannabinol)

MDA (Methylenedioxyamphetamine) Metabolite for Methylenedioxymethamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

MDMA (Methylenedioxymethamphetamine)

Methamphetamines (Desoxyn)

Methadone (Dolophine)

Methylenedioxyamphetamine (MDA) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (MDMA)

Morphine (Avinza)

Nembutal (Pentobarbital)

Noroxycodone

Noroxymorphone

Opiates

Oxycodone (Oxycontin, Percodan)

Oxycontin (Oxycodone)

Panlor DC (Dihydrocodone)

PCP (Phencyclidine)

Pentobarbital (Nembutal)

Percodan (Oxycodone)

Phenobarbital

Rocket Fuel (Phencyclidine)

Secobarbital (Seconal)

Seconal (Secobarbital)

Solfoton (Phenobarbital)

Speed (Amphetamines)

Sublimaze (Fentanyl)

Super Weed

TCP (Phencyclidine)

Tetrahydrocannabinol (THC)

THC (Tetrahydrocannabinol)

ConZip

Tramadol

Ultracet

Ultram

Ultram ER

Clonazepam

Klonopin (Clonazepam)

Rivotril (Clonazepam)

Ativan (Lorazepam)

Zolpidem

Oxazepam (separate prescribable drug and metabolite of clorazepate, halazepam, prazepam, medazepam, temazepam, and diazepam

7-Amino Flunitrazepam (metabolite of Flunitrazepam) (Rohypnol)

7-aminoclonazepam

Alprazolam (Xanax)

Benzodiazepines

Chlordiazepoxide (Librium)

Dalmane (Flurazepam)

Diazepam (Valium)

Flunitrazepam (Rohypnol)

Flurazepam (Dalmane)

Halcion (Triazolam)

Librium (Chlordiazepoxide)

Lorazepam (Ativan)

Oxazepam (Serax)

Restoril (Temazepam)

Rohypnol (Flunitrazepam)

Serax (Oxazepam)

Synalogs DC (Dihydrocodone)

Temazepam (Restoril)

Triazolam (Halcion)

Tylenol 3 (Codeine)

Valium (Diazepam)

Vicodin (Hydrocodone)

Xanax (Alprazolam)

Specimen Type
Describes the specimen type validated for testing

Fluid

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation:

1. For 15 to 60 minutes before specimen collection, the patient should abstain from eating food.

2. If the patient has recently taken an oral medication or used an inhaled medication, wait 2 hours before collecting the specimen.

3. Patient must empty mouth of any gum, food, or tobacco prior to oral fluid collection. If patient's mouth is not empty immediately before collection, have them rinse their mouth with water (up to 4 oz) and wait 10 minutes before collection. The patient may discard or drink the water after rinsing.

 

Supplies: Quantisal Oral Fluid Collection Device (T980)

Note: Check expiration date on Quantisal packaging

Container/Tube: Quantisal collection device

Specimen Volume: 1 mL

Collection Instructions:

1. For complete instructions, see Oral Fluid Specimen Collection Instructions for Controlled Substance Monitoring.

2. Peel open package and remove collector by the handle. Do not touch the collection pad with fingers before or after specimen collection. To expedite the collection process, move tongue side to side to accumulate saliva in mouth before starting. Keep the tip of the device pointed down.

3. Position collector under tongue and close mouth. Keep head down to allow gravity to help with saliva collection.

Important: Do not chew on pad, talk, or remove collector from mouth until indicator turns BLUE, or until 10 minutes has passed, whichever occurs first.

4. Hold transport tube in an upright position and uncap by pushing up with thumbs. Do not stand tube on table. Do not spill or empty the liquid from tube.

5. Insert collector into the uncapped transport tube and replace cap. Do not place collector back in mouth after it has been placed in the transport tube.

6. Snap cap firmly for transport. Place center of specimen seal on top of tube and press down both sides.

7. Complete paperwork and send sample to laboratory.

8. Send in original tube. Do not aliquot.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

See Specimen Required

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Fluid Ambient (preferred) 7 days
Frozen 28 days
Refrigerated 7 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Monitoring acute (ie, short-term) drug use in addiction treatment or pain management settings as part of a rotational drug testing strategy

 

Presumptive screening for amphetamine, methamphetamine, opioids/opiates (targeting morphine, oxymorphone, oxycodone, hydrocodone, 6-monoacetylmorphine, tramadol, buprenorphine, fentanyl, and methadone), PCP (phencyclidine), cocaine metabolite (targeting benzoylecgonine), benzodiazepines (targeting oxazepam, lorazepam, and clonazepam), zolpidem, barbiturates (targeting phenobarbital), methylphenidate, and THC-COOH (marijuana metabolite) in oral fluid specimens

 

This test is not intended for forensic or medico-legal purposes (ie, employee drug testing or settings where chain-of-custody is required).

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Drug abuse is a major social and medical issue and usually requires costly interventions for the treatment and rehabilitation of abusers. This qualitative test screens for commonly prescribed and/or abused drugs/drug classes in human oral fluid specimens. It uses a noninvasive specimen collection method, which can be observed. This test may be used for screening samples for compliance monitoring of prescription drugs in a point of care setting.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Not detected

 

Positives are reported with a qualitative result.

Cutoff concentrations by competitive chemiluminescent immunoassay:

Opioids:

6-Acetylmorphine: 5 ng/mL

Morphine: 10 ng/mL

Hydrocodone: 10 ng/mL

Oxycodone: 10 ng/mL

Oxymorphone: 10 ng/mL

Methadone: 10 ng/mL

Fentanyl: 1 ng/mL

Tramadol: 5 ng/mL

Buprenorphine: 1 ng/mL

 

Benzodiazepines:

Oxazepam: 10 ng/mL

Clonazepam: 10 ng/mL

Lorazepam: 10 ng/mL

 

Non-Benzodiazepine: Zolpidem: 10 ng/mL

 

Stimulants:

Amphetamine: 20 ng/mL

Methamphetamine: 10 ng/mL

Methylphenidate: 100 ng/mL

Cocaine Metabolite (BE): 30 ng/mL

 

PCP, Phencyclidine: 5 ng/mL

Marijuana metabolite (THC-COOH): 10 ng/mL

Barbiturates, Phenobarbital: 50 ng/mL

Interpretation
Provides information to assist in interpretation of the test results

This test is intended to screen for amphetamine, methamphetamine, opioids/opiates (targeting morphine, oxymorphone, oxycodone, hydrocodone, 6-monoacetylmorphine, tramadol, buprenorphine, fentanyl, and methadone), PCP (phencyclidine), cocaine metabolite (targeting benzoylecgonine), benzodiazepines (targeting oxazepam, lorazepam, and clonazepam), zolpidem, barbiturates (targeting phenobarbital), methylphenidate, and THC-COOH (marijuana metabolite) in oral fluid specimens. The limit of detection for each of these drug groups varies (see Reference Values). A positive finding for one of these drugs or metabolites is an indication for the presence of the drug of abuse or cross reactivity with other structurally similar commonly prescribed drugs.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

It is possible that substances other than those investigated may interfere and cause a false-positive screening result. If specific drug identification is required, urine testing is recommended;  order CSMPU / Controlled Substance Monitoring Panel, Random, Urine, which uses high-resolution accurate mass spectrometry-based targeted testing.

 

In instances where an oral fluid specimen cannot be collected (eg, dry mouth), providers should consider alternative specimen collection methods (eg, urine).

 

This test is not appropriate for use in forensic or employment settings (ie, medico-legal, chain-of-custody).

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Appl Lab Med. 2018;2(4):489-526. doi:10.1373/jalm.2017.023341

2. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem. 2009;55(11):1910-31. doi:10.1373/clinchem.2008.108670.

3. Huestis MA, Verstraete A, Kwong TC, Morland J, Vincent MJ, de la Torre R. Oral fluid testing: promises and pitfalls. Clin Chem. 2011;57(6):805-10. doi:10.1373/clinchem.2010.152124

Method Description
Describes how the test is performed and provides a method-specific reference

The oral fluid sample, collected with the Quantisal device, is screened using a competitive immunoassay to indicate the presence of any of the drugs/drug classes or their cross reactivity with other structurally similar commonly prescribed or abused drugs. Screening for amphetamine, methamphetamine, opioids/opiates (targeting morphine, oxymorphone, oxycodone, hydrocodone, 6-monoacetyl morphine, tramadol, buprenorphine, fentanyl, and methadone), phencyclidine (PCP), cocaine metabolite (targeting benzoylecgonine), benzodiazepines (targeting oxazepam, lorazepam, and clonazepam), zolpidem, barbiturates (targeting phenobarbital), methylphenidate, and THC-COOH (marijuana metabolite) is accomplished using a competitive chemiluminescent immunoassay.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

2 weeks

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

80307

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
CSMOF Controlled Substance Panel, OF 20787-8
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
621486 Opioids, Morphine, OF 32100-0
621485 Opioids, 6-acetylmorphine, OF 32099-4
621487 Opioids, Hydrocodone, OF 32080-4
621488 Opioids, Oxycodone, OF 69356-4
621489 Opioids, Oxymorphone, OF In Process
621490 Opioids, Methadone, OF 72626-5
621491 Opioids, Fentanyl, OF 87815-7
621492 Opioids, Tramadol, OF 74110-8
621493 Opioids, Buprenorphine, OF 73942-5
621494 Benzodiazepines, Oxazepam, OF 72614-1
621495 Benzodiazepines, Clonazepam, OF 61039-4
621496 Benzodiazepines, Lorazepam, OF 61044-4
621497 Non-Benzodiazepine, Zolpidem, OF 87820-7
621498 Stimulants, Amphetamine, OF 40799-9
621499 Stimulants, Methamphetamine, OF 40804-7
621500 Stimulants, Methylphenidate, OF 87805-8
621501 Stimulants, Cocaine Metabolite (BE), OF 40802-1
621502 PCP, Phencyclidine, OF 40808-8
621503 Marijuana metabolite (THC-COOH), OF 40801-3
621504 Barbiturates, Phenobarbital, OF 32108-3
621484 Controlled Substance Interpretation 69050-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | PHP Pdf | CMS Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports